Celltrion has announced that it completed the second biosimilar application for its monoclonal antibody infliximab on August 8, 2014. Click here for a Jones Day Commentary on the new biosimilar application process.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.